Quick Facts
FONT-SIZE Plus   Neg
Share SHARE
mail  E-MAIL

Genzyme, Veracyte Announce U.S. Availability Of Afirma Thyroid FNA Analysis

4/16/2012 12:02 PM ET

Genzyme, a Sanofi company (SNY: Quote), and Veracyte, Inc.,said Monday that the Afirma Thyroid FNA Analysis, an innovative approach for improved thyroid nodule diagnosis, is now available to patients across the United States.

The Afirma Thyroid FNA Analysis combines expert cytopathology assessment of thyroid nodule fine needle aspiration samples, with the Afirma Gene Expression Classifier, a novel genomic test, used to resolve inconclusive results and thus help patients whose nodules are actually benign avoid unnecessary surgery.

Two independent clinical studies to date have shown that the Afirma Gene Expression Classifier can reclassify patients with indeterminate thyroid FNA results as "benign" with the same degree of accuracy as a benign cytopathology diagnosis.

Click here to receive FREE breaking news email alerts for Sanofi and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
New home sales in the U.S. unexpectedly showed a substantial decrease in the month of March, according to a report released by the Commerce Department on Wednesday, with sales falling to their lowest level in eight months. The report said new home sales plunged 14.5 percent to an annual rate of 384,000 in March from the revised February rate of 449,000. Euro area's government deficit shrunk last year to match the EU target, while public debt rose and remained above the official ceiling, figures from the Eurostat showed Wednesday. The shrunken government deficits suggest that euro area might be leaving behind the worst troubles of the financial crisis,... Following the strong upward move seen over the past few sessions, stocks may give back some ground in early trading on Wednesday. The major index futures are currently pointing to a modestly lower open for the markets, with the Dow futures down by 6 points.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.